The estimated Net Worth of Michael J. Kaufman is at least $79.1 mil dollars as of 15 July 2021. Michael Kaufman owns over 40,000 units of Mersana Therapeutics Inc stock worth over $79,137 and over the last 7 years he sold MRSN stock worth over $0. In addition, he makes $0 as Senior Vice President - Chemistry y Manufacturing and Controls at Mersana Therapeutics Inc.
Sign up
Michael Kaufman MRSN stock SEC Form 4 insiders trading
Michael has made over 2 trades of the Mersana Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of MRSN stock worth $70,800 on 15 July 2021.
The largest trade he's ever made was exercising 40,000 units of Mersana Therapeutics Inc stock on 15 July 2021 worth over $70,800. On average, Michael trades about 7,778 units every 30 days since 2018. As of 15 July 2021 he still owns at least 44,710 units of Mersana Therapeutics Inc stock.
You can see the complete history of Michael Kaufman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Kaufman biography
Dr. Michael Kaufman Ph.D. serves as Senior Vice President - Chemistry, Manufacturing and Controls of the Company. Previously, from 2012 to 2016, Dr. Kaufman served as Vice President, Technical Development at Biogen, Inc. Before Biogen, Dr. Kaufman spent 10 years at Millennium Pharmaceuticals, prior to and after it became a wholly owned subsidiary of Takeda Pharmaceuticals, most recently as Vice President, Pharmaceutical Sciences. Before that, he spent 15 years at Merck and Co., Inc. serving in various roles. Dr. Kaufman received a B.S. in Chemistry from the State University of New York, Stony Brook and a Ph.D. in Physical Organic Chemistry from the University of California, Berkeley.
How old is Michael Kaufman?
Michael Kaufman is 62, he's been the Senior Vice President - Chemistry y Manufacturing and Controls of Mersana Therapeutics Inc since 2016. There are 2 older and 18 younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.
What's Michael Kaufman's mailing address?
Michael's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Insiders trading at Mersana Therapeutics Inc
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
What does Mersana Therapeutics Inc do?
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
What does Mersana Therapeutics Inc's logo look like?
Complete history of Michael Kaufman stock trades at Mersana Therapeutics Inc
Mersana Therapeutics Inc executives and stock owners
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Anna Protopapas,
President, Chief Executive Officer, Director -
Dirk Huebner,
Chief Medical Officer -
Timothy Lowinger,
Chief Science and Technology Officer -
Brian DeSchuytner,
Senior Vice President - Finance and Product Strategy -
Anna Protopapas,
Pres, CEO & Director -
Anna Protopapas M.B.A.,
Pres, CEO & Director -
Dr. Timothy B. Lowinger,
Chief Science & Technology Officer -
Brian C. DeSchuytner,
Sr. VP & CFO -
Dr. Arvin Yang M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Alejandra Veronica Carvajal J.D.,
SVP, Sec. & Chief Legal Officer -
Dr. Tushar Misra Ph.D.,
SVP & Chief Manufacturing Officer -
David Mott,
Independent Chairman of the Board -
Lawrence Alleva,
Independent Director -
Willard Dere,
Independent Director -
Andrew Hack,
Independent Director -
Kristen Hege,
Independent Director -
Martin Huber,
Independent Director -
Eva Jack,
Chief Business Officer -
Chuck Miller,
Senior Vice President - Regulatory Affairs -
Michael Kaufman,
Senior Vice President - Chemistry, Manufacturing and Controls -
Alejandra Veronica Carvajal,
Sr. VP & Chief Legal Officer -
Carla Poulson,
Chief HR Officer -
Radha Iyengar,
VP of Legal Operations -
Sarah Carmody,
Exec. Director of Investor Relations & Corp. Communications -
Ashish Mandelia,
VP, Controller & Principal Accounting Officer -
Mikhail Papisov Ph.D.,
Co-Founder -
Llc Fmr,
-
Peter J Barris,
10% owner -
Forest Baskett,
10% owner -
M James Barrett,
10% owner -
Ravi Viswanathan,
10% owner -
Peter W. Sonsini,
10% owner -
Enterprise Associates 14, L...,
-
Patrick J Kerins,
10% owner -
Scott D Sandell,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Sara M. Nayeem,
Director -
Wayne Foster,
Vice President of Finance -
Donald A Bergstrom,
Chief Medical Officer -
David A Spellman,
Chief Financial Officer -
Enterprise Associates 14, L...,
-
Partners 14, L.P.Nea 14 Gp,...,
-
Enterprise Associates 14, L...,
-
Enterprise Associates 14, L...,
10% owner -
Allene M. Diaz,
Director -
Mohan Bala,
SVP, Chief Development Officer -
Arvin Yang,
SVP, Chief Medical Officer -
Ashish Mandelia,
VP, Chief Accounting Officer -
Tushar Misra,
SVP, Chief Manuf. Officer